Skip to content

    Royalty Pharma (RPRX) stock price & financials

    View RPRX earnings calls

    Overview

    Price

    Market Cap

    Sector

    Rank

    Performance+68.7% 1Y

    Financials

    Income Statement

    Financial Trajectories

    11
    Quarterly
    MetricQ3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Trend
    EarningsRevenue
    $564.69M
    $593.64M
    $568.25M
    $578.66M
    $609.29M
    +7.9%
    $621.99M
    +4.8%
    $630.58M
    +11.0%
    $674.14M
    +16.5%
    Strengthening
    Operating Profit
    $735.07M
    $361.51M
    $534.18M
    $209.80M
    $427.16M
    -41.9%
    $388.38M
    +7.4%
    $563.04M
    +5.4%
    $133.12M
    -36.5%
    Weakening
    Net Profit
    $543.99M
    $208.21M
    $239.35M
    $32.18M
    $288.22M
    -47.0%
    $211.21M
    +1.4%
    $294.69M
    +23.1%
    $17.88M
    -44.4%
    Weakening
    EPS
    $1.22
    $0.55
    $0.08
    $0.67
    -45.1%
    $0.67
    +21.8%
    $0.04
    -50.0%
    Weakening
    Other Income
    $71.28M
    -$27.16M
    -$99.75M
    -$117.16M
    $17.05M
    -76.1%
    -$35.47M
    -30.6%
    -$94.78M
    +5.0%
    -$51.63M
    +55.9%
    Strengthening
    Interest
    $66.51M
    $65.76M
    $65.26M
    $68.67M
    $79.56M
    +19.6%
    $94.17M
    +43.2%
    $93.72M
    +43.6%
    $93.62M
    +36.3%
    Strengthening
    Depreciation
    Profit before Tax
    $806.36M
    $334.35M
    $434.43M
    $92.64M
    $444.21M
    -44.9%
    $352.91M
    +5.6%
    $468.26M
    +7.8%
    $81.49M
    -12.0%
    Stable
    MarginsOPM
    130.2%
    60.9%
    94.0%
    36.3%
    70.1%
    -46.1%
    62.4%
    +2.5%
    89.3%
    -5.0%
    19.8%
    -45.5%
    Weakening
    Tax
    0.0%
    0.0%
    0.0%
    0.0%
    0.0%
    0.0%
    0.0%
    0.0%
    ReturnsROIC
    22.1%
    8.5%
    9.7%
    1.3%
    11.7%
    -47.0%
    8.6%
    +1.4%
    12.0%
    +23.1%
    0.7%
    -44.4%
    Weakening

    Balance Sheet

    Balance Sheet

    USD · Annual
    Line itemFY18FY19FY20FY21FY22FY23FY24FY25TTM
    AssetsCash & Equivalents$1.92B$246.20M$1.01B$1.54B$1.71B$477.01M$929.03M$618.70M$811.99M
    Short-Term Investments
    Total Current Assets$832.07M$2.70B$2.88B$2.55B$1.27B$1.80B$1.53B$1.76B
    Net PP&E
    Goodwill$0$924.63M$923.53M
    Intangibles$51.72M$28.67M$5.67M$0
    Total Assets$12.45B$16.02B$17.52B$16.81B$16.38B$18.22B$19.62B$19.82B
    LiabilitiesTotal Current Liabilities$333.42M$307.89M$171.25M$1.17B$161.38M$1.25B$636.21M$630.93M
    Short-Term Debt$281.98M$0$0$997.51M$0$997.77M$380.00M$380.00M
    Long-Term Debt$5.96B$5.82B$7.10B$6.12B$6.14B$6.61B$8.57B$8.58B
    Long-Term Leases
    Total Liabilities$6.31B$6.12B$7.27B$7.29B$6.30B$7.88B$9.91B$10.03B
    EquityCommon Stock & APIC
    Retained Earnings$2.83B$1.92B$2.26B$1.96B$2.52B$2.85B$2.36B$2.46B
    Total Equity$4.55B$6.14B$9.90B$10.25B$9.53B$10.08B$10.34B$9.71B$9.79B
    HighlightsNet Cash / (Debt)-$5.99B-$4.81B-$5.56B-$5.41B-$5.66B-$6.68B-$8.33B-$8.15B

    Cash Flow

    Cash Flow

    USD · Annual
    Line itemFY18FY19FY20FY21FY22FY23FY24FY25TTM
    ActivitiesCash from Operating$1.62B$1.67B$2.03B$2.02B$2.14B$2.99B$2.77B$2.49B$2.98B
    Cash from Investing$303.42M-$2.15B-$2.76B-$1.87B-$1.03B-$2.07B-$2.68B-$1.61B-$2.51B
    Cash from Financing-$1.38B-$1.19B$1.49B$385.11M-$944.86M-$2.15B$361.14M-$1.19B-$282.68M
    SummaryCapital Expenditure
    Free Cash Flow
    FCF Margin

    Ratios